MOTS-c vs SS-31 (Elamipretide)
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
MOTS-c
MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA type-c) is a mitochondrial-derived peptide that plays a key role in metabolic regulation and has emerged as a significant longevity research target.
Full details →SS-31 (Elamipretide)
SS-31, also known as Elamipretide or Bendavia, is a mitochondria-targeted tetrapeptide. It has been studied extensively for mitochondrial diseases, heart failure, and age-related decline in mitochondrial function.
Full details →Side-by-Side Comparison
| Aspect | MOTS-c | SS-31 (Elamipretide) |
|---|---|---|
| Dose Range | 5 mg–10 mg | 20 mg–40 mg |
| Frequency | Less than daily | 1x daily |
| Cycle Length | 8–12 weeks | 4–12 weeks |
| Route | subcutaneous | subcutaneous |
| Mechanism | Activates AMPK pathway, enhances glucose uptake in skeletal muscle, improves insulin sensitivity, and regulates mitochondrial function. Acts as a metabolic hormone affecting whole-body energy homeostasis. | Concentrates in the inner mitochondrial membrane where it binds to cardiolipin, stabilizing electron transport chain function, reducing reactive oxygen species, and improving ATP production efficiency. |
| Typical Dosage | Research protocols typically use 5-10mg administered subcutaneously several times per week. Optimal dosing not yet established. | Clinical trials have used IV infusions of 0.25mg/kg for acute conditions. Subcutaneous dosing protocols for research use typically range from 1-5mg daily. |
| Administration | Subcutaneous injection. Often combined with exercise protocols as it enhances exercise capacity and metabolic adaptation. | Can be administered IV or subcutaneously. Most clinical research has used IV administration for cardiac conditions. |
| Side Effects | Limited human data. Animal studies show good tolerability. May affect energy levels and exercise performance. | Generally well-tolerated. Clinical trials reported injection site reactions and occasional headache. |
| Best For |
What They Have in Common
MOTS-c, SS-31 (Elamipretide) are both commonly used for:
Key Differences
Unique to MOTS-c:
Unique to SS-31 (Elamipretide):
Which Has Stronger Evidence?
- Anti-Aging & Longevity: SS-31 (Elamipretide) has stronger research support.
| Goal | MOTS-c | SS-31 (Elamipretide) |
|---|---|---|
| Anti-Aging & Longevity | medium | high |
Key Studies
MOTS-c
- MOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1α/AMPK-dependent manner.
Free radical biology & medicine, 2026
- MOTS-c attenuates lung ischemia-reperfusion injury via MYH9-Dependent nuclear translocation and transcriptional activation of antioxidant genes.
Redox biology, 2025
- MOTS-c: Magical Molecule for Diabetic Cardiomyopathy?
Cardiovascular drugs and therapy, 2025
SS-31 (Elamipretide)
- Elamipretide: First Approval.
Drugs, 2026
- Targeting Mitochondrial Dysfunction With Elamipretide (SS-31) Improves Skeletal Muscle Performance in a HFpEF Rat Model.
Circulation. Heart failure, 2026
- Elamipretide (SS-31) and Nicotinamide Mononucleotide (NMN) Combination Therapy Targets TREM2 to Mitigate Post-ischemic Brain Injury in Mice.
Neurochemical research, 2026
Ready to Learn More?
Looking for trusted sources?